Story perspectives

FDA Approves Arrowhead's Redemplo, Promising $1.4B Revenue

11/19/2025

25 5

Summary

Story summary

U.S. Food and Drug Administration approves Arrowhead Pharmaceuticals' Redemplo for familial chylomicronemia syndrome on November 18, 2025.
The approval marks Arrowhead's first marketed product and the second U.S. treatment for the condition.
Redemplo costs $60,000 per year and is dosed quarterly.
In trials, Redemplo reduced triglycerides by 80% and pancreatitis risk by 83%.
Analysts project about $1.4 billion in revenue by 2031; Arrowhead partners with Sanofi for Greater China.

1 of 1

Story summary

U.S. Food and Drug Administration approves Arrowhead Pharmaceuticals' Redemplo for familial chylomicronemia syndrome on November 18, 2025.
The approval marks Arrowhead's first marketed product and the second U.S. treatment for the condition.
Redemplo costs $60,000 per year and is dosed quarterly.
In trials, Redemplo reduced triglycerides by 80% and pancreatitis risk by 83%.
Analysts project about $1.4 billion in revenue by 2031; Arrowhead partners with Sanofi for Greater China.